Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Multiple Sclerosis Centre, S. Andrea Hospital, Rome, Italy Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.
Luca
L
Prosperini
Multiple Sclerosis Centre, S. Andrea Hospital, Rome, Italy Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.
Floriana
F
De Angelis
Multiple Sclerosis Centre, S. Andrea Hospital, Rome, Italy Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.
Rosanna
R
De Angelis
Multiple Sclerosis Centre, S. Andrea Hospital, Rome, Italy Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.
Fulvia
F
Fanelli
Multiple Sclerosis Centre, S. Andrea Hospital, Rome, Italy Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.
Carlo
C
Pozzilli
D000293:Adolescent; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D004185:Disability Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology*; D000069442:Natalizumab; D059906:Neuroimaging; D020127:Recovery of Function / Q000187:drug effects*; D012008:Recurrence; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab
MRI; MULTIPLE SCLEROSIS